FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3026899880> ?p ?o ?g. }

• W3026899880 endingPage "5024" @default.
• W3026899880 startingPage "5015" @default.
• W3026899880 abstract "Abstract Background There is increasing evidence that immunotherapy with nivolumab, an anti‐programmed death 1 monoclonal antibody, is effective in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). However, the predictive role of hematological inflammatory markers such as neutrophil‐to‐lymphocyte ratio (NLR) and the modified Glasgow prognostic score (mGPS) in patients with R/M SCCHN treated with nivolumab remains unclear. Methods We conducted a multi‐institutional cohort study to evaluate the impact of pretreatment NLR and mGPS on overall survival (OS) and progression‐free survival (PFS) in patients with R/M SCCHN treated with nivolumab in Japan. From 2012 to 2013, 102 patients were eligible, of whom 88 were finally included in the analysis. mGPS was calculated as follows: mGPS of 0, C‐reactive protein (CRP) ≤1.0 mg/dL; 1, CRP > 1.0 mg/dL; and 2, CRP > 1.0 mg/dL and albumin < 3.5 mg/dL. Optimal cutoff point of dichotomized NLR was calculated using the area under the receiver operating characteristic curve (AUROC). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) were estimated by Cox proportional hazard models adjusted by potential confounders. Results Higher NLR was significantly associated with worse survival (1‐year OS: 45.3% vs 16.3%, log‐rank P ‐value < .001, adjusted HR: 4.40 (95% CIs: 1.78‐10.88); one‐year PFS: 39.1% vs 9.0%, P ‐value = .001, adjusted HR: 3.37 (95% CI: 1.64‐6.92)). In addition, high mGPS (=2) was significantly associated with worse survival compared to low mGPS (=0) (1‐year OS: 37.4% vs 26.1%, P ‐value = .004, adjusted HR: 4.20 (95% CI:1.54‐11.49); 1‐year PFS: 41.5% vs 24.8%, P ‐value = .007, adjusted HR: 2.01 (95% CI: 0.87‐4.68)). These associations were consistent with subgroup analyses stratified by potential confounders. Conclusions Pretreatment NLR and mGPS might be predictive markers of survival in patients with R/M SCCHN treated with nivolumab." @default.
• W3026899880 created "2020-05-29" @default.
• W3026899880 creator A5004609431 @default.
• W3026899880 creator A5007923806 @default.
• W3026899880 creator A5008563527 @default.
• W3026899880 creator A5019694045 @default.
• W3026899880 creator A5022615176 @default.
• W3026899880 creator A5023589367 @default.
• W3026899880 creator A5028984479 @default.
• W3026899880 creator A5044023639 @default.
• W3026899880 creator A5063854016 @default.
• W3026899880 creator A5066969352 @default.
• W3026899880 creator A5068216885 @default.
• W3026899880 creator A5076710089 @default.
• W3026899880 creator A5089494497 @default.
• W3026899880 date "2020-05-22" @default.
• W3026899880 modified "2023-10-08" @default.
• W3026899880 title "Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients" @default.
• W3026899880 cites W1837379120 @default.
• W3026899880 cites W1964795510 @default.
• W3026899880 cites W1981851073 @default.
• W3026899880 cites W1988902102 @default.
• W3026899880 cites W1992925961 @default.
• W3026899880 cites W2053545935 @default.
• W3026899880 cites W2064983345 @default.
• W3026899880 cites W2085458222 @default.
• W3026899880 cites W2089783760 @default.
• W3026899880 cites W2091553144 @default.
• W3026899880 cites W2133824413 @default.
• W3026899880 cites W2154966510 @default.
• W3026899880 cites W2157617993 @default.
• W3026899880 cites W2168631000 @default.
• W3026899880 cites W2169372773 @default.
• W3026899880 cites W2407490762 @default.
• W3026899880 cites W2506130304 @default.
• W3026899880 cites W2522869448 @default.
• W3026899880 cites W2529484692 @default.
• W3026899880 cites W2537220355 @default.
• W3026899880 cites W2553868801 @default.
• W3026899880 cites W2592159070 @default.
• W3026899880 cites W2598236996 @default.
• W3026899880 cites W2740518609 @default.
• W3026899880 cites W2750862728 @default.
• W3026899880 cites W2769732660 @default.
• W3026899880 cites W2771341529 @default.
• W3026899880 cites W2779221466 @default.
• W3026899880 cites W2782319564 @default.
• W3026899880 cites W2783295481 @default.
• W3026899880 cites W2788797147 @default.
• W3026899880 cites W2794739281 @default.
• W3026899880 cites W2799372507 @default.
• W3026899880 cites W2802567595 @default.
• W3026899880 cites W2883706035 @default.
• W3026899880 cites W2889205080 @default.
• W3026899880 cites W2896318583 @default.
• W3026899880 cites W2922097565 @default.
• W3026899880 cites W2971671094 @default.
• W3026899880 doi "https://doi.org/10.1002/cam4.3124" @default.
• W3026899880 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7367642" @default.
• W3026899880 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32441463" @default.
• W3026899880 hasPublicationYear "2020" @default.
• W3026899880 type Work @default.
• W3026899880 sameAs 3026899880 @default.
• W3026899880 citedByCount "23" @default.
• W3026899880 countsByYear W30268998802020 @default.
• W3026899880 countsByYear W30268998802021 @default.
• W3026899880 countsByYear W30268998802022 @default.
• W3026899880 countsByYear W30268998802023 @default.
• W3026899880 crossrefType "journal-article" @default.
• W3026899880 hasAuthorship W3026899880A5004609431 @default.
• W3026899880 hasAuthorship W3026899880A5007923806 @default.
• W3026899880 hasAuthorship W3026899880A5008563527 @default.
• W3026899880 hasAuthorship W3026899880A5019694045 @default.
• W3026899880 hasAuthorship W3026899880A5022615176 @default.
• W3026899880 hasAuthorship W3026899880A5023589367 @default.
• W3026899880 hasAuthorship W3026899880A5028984479 @default.
• W3026899880 hasAuthorship W3026899880A5044023639 @default.
• W3026899880 hasAuthorship W3026899880A5063854016 @default.
• W3026899880 hasAuthorship W3026899880A5066969352 @default.
• W3026899880 hasAuthorship W3026899880A5068216885 @default.
• W3026899880 hasAuthorship W3026899880A5076710089 @default.
• W3026899880 hasAuthorship W3026899880A5089494497 @default.
• W3026899880 hasBestOaLocation W30268998801 @default.
• W3026899880 hasConcept C121608353 @default.
• W3026899880 hasConcept C126322002 @default.
• W3026899880 hasConcept C143998085 @default.
• W3026899880 hasConcept C207103383 @default.
• W3026899880 hasConcept C2776530083 @default.
• W3026899880 hasConcept C2776694085 @default.
• W3026899880 hasConcept C2776833033 @default.
• W3026899880 hasConcept C2777701055 @default.
• W3026899880 hasConcept C2778496288 @default.
• W3026899880 hasConcept C2780030458 @default.
• W3026899880 hasConcept C44249647 @default.
• W3026899880 hasConcept C50382708 @default.
• W3026899880 hasConcept C58471807 @default.
• W3026899880 hasConcept C71924100 @default.
• W3026899880 hasConcept C90924648 @default.

• next